Marisa H. Miceli

5.0k total citations · 1 hit paper
85 papers, 3.0k citations indexed

About

Marisa H. Miceli is a scholar working on Epidemiology, Infectious Diseases and Oncology. According to data from OpenAlex, Marisa H. Miceli has authored 85 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Epidemiology, 59 papers in Infectious Diseases and 14 papers in Oncology. Recurrent topics in Marisa H. Miceli's work include Antifungal resistance and susceptibility (53 papers), Fungal Infections and Studies (49 papers) and Infectious Diseases and Mycology (12 papers). Marisa H. Miceli is often cited by papers focused on Antifungal resistance and susceptibility (53 papers), Fungal Infections and Studies (49 papers) and Infectious Diseases and Mycology (12 papers). Marisa H. Miceli collaborates with scholars based in United States, Belgium and Italy. Marisa H. Miceli's co-authors include Samuel A. Lee, Carol A. Kauffman, José A. Díaz, Elias Anaissie, Bart Barlogie, Monica Grazziutti, Julie M. Steinbrink, Gail L. Woods, Johan Maertens and Kathleen A. Linder and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Marisa H. Miceli

79 papers receiving 2.9k citations

Hit Papers

Emerging opportunistic yeast infections 2011 2026 2016 2021 2011 200 400 600

Peers

Marisa H. Miceli
Harrys A. Torres United States
Dionysios Neofytos Switzerland
Amar Safdar United States
Neil M. Ampel United States
Jong Hee Shin South Korea
P. M. Shah Germany
Harrys A. Torres United States
Marisa H. Miceli
Citations per year, relative to Marisa H. Miceli Marisa H. Miceli (= 1×) peers Harrys A. Torres

Countries citing papers authored by Marisa H. Miceli

Since Specialization
Citations

This map shows the geographic impact of Marisa H. Miceli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marisa H. Miceli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marisa H. Miceli more than expected).

Fields of papers citing papers by Marisa H. Miceli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marisa H. Miceli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marisa H. Miceli. The network helps show where Marisa H. Miceli may publish in the future.

Co-authorship network of co-authors of Marisa H. Miceli

This figure shows the co-authorship network connecting the top 25 collaborators of Marisa H. Miceli. A scholar is included among the top collaborators of Marisa H. Miceli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marisa H. Miceli. Marisa H. Miceli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spec, Andrej, George R. Thompson, Marisa H. Miceli, et al.. (2024). MSG-15: Super-Bioavailability Itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses—A Multicenter, Open-Label, Randomized Comparative Trial. Open Forum Infectious Diseases. 11(3). ofae010–ofae010. 11 indexed citations
2.
Zhou, Shiwei, Carol A. Kauffman, & Marisa H. Miceli. (2024). Blastomycosis. Infectious Disease Clinics of North America. 39(1). 163–181.
3.
Nguyen, M. Hong, Luis Ostrosky‐Zeichner, Peter G. Pappas, et al.. (2023). Real-world Use of Mold-Active Triazole Prophylaxis in the Prevention of Invasive Fungal Diseases: Results From a Subgroup Analysis of a Multicenter National Registry. Open Forum Infectious Diseases. 10(9). ofad424–ofad424. 15 indexed citations
4.
Linder, Kathleen A. & Marisa H. Miceli. (2023). Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-free DNA Testing in the Management of Patients With Suspected Infectious Diseases. Open Forum Infectious Diseases. 10(8). ofad385–ofad385. 5 indexed citations
5.
Ostrosky‐Zeichner, Luis, M. Hong Nguyen, Joseph Bubalo, et al.. (2022). Multicenter Registry of Patients Receiving Systemic Mold-Active Triazoles for the Management of Invasive Fungal Infections. Infectious Diseases and Therapy. 11(4). 1609–1629. 11 indexed citations
6.
Maurer, Stephen M., Kathleen A. Linder, Carol A. Kauffman, et al.. (2022). Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies. Bone Marrow Transplantation. 57(12). 1820–1826. 1 indexed citations
7.
Steinbrink, Julie M. & Marisa H. Miceli. (2021). Mucormycosis. Infectious Disease Clinics of North America. 35(2). 435–452. 70 indexed citations
8.
Linder, Kathleen A., Tejal Gandhi, & Marisa H. Miceli. (2019). Treatment Failure of Isavuconazole in a Patient with Cryptococcosis. Mycopathologia. 184(5). 667–670. 8 indexed citations
9.
Tang, Laura, Bernard L. Marini, Lydia L. Benitez, et al.. (2017). Risk factors for subtherapeutic levels of posaconazole tablet. Journal of Antimicrobial Chemotherapy. 72(10). 2902–2905. 38 indexed citations
10.
Miceli, Marisa H. & Carol A. Kauffman. (2015). Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clinical Infectious Diseases. 61(10). 1558–1565. 248 indexed citations
11.
Miceli, Marisa H., et al.. (2009). A Case of Person-to-Person Transmission of Q Fever from an Active Duty Serviceman to His Spouse. Vector-Borne and Zoonotic Diseases. 10(5). 539–541. 32 indexed citations
12.
Miceli, Marisa H. & Elias Anaissie. (2009). Clinical trial design for invasive aspergillosis: time to cast a different mold. Medical Mycology. 47(s1). S343–S348. 2 indexed citations
13.
Miceli, Marisa H., et al.. (2008). Pulmonary Artery Access Embolization in Patients with Massive Hemoptysis in Whom Bronchial and/or Nonbronchial Systemic Artery Embolization Is Contraindicated. CardioVascular and Interventional Radiology. 31(3). 633–637. 3 indexed citations
15.
Woods, Gail L., Marisa H. Miceli, Monica Grazziutti, et al.. (2007). Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis. Cancer. 110(4). 830–834. 90 indexed citations
16.
Miceli, Marisa H., Dong Lei, Monica Grazziutti, et al.. (2006). Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplantation. 37(9). 857–864. 87 indexed citations
17.
Grazziutti, Monica, Dong Lei, Marisa H. Miceli, et al.. (2006). Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplantation. 38(7). 501–506. 86 indexed citations
18.
Grazziutti, Monica, Dong Lei, Marisa H. Miceli, et al.. (2006). Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients. Bone Marrow Transplantation. 37(4). 403–409. 16 indexed citations
19.
Tersigni, R, et al.. (2004). [The surgical treatment of gastric carcinoma. Evolution in surgical technique and staging in a series of 194 patients].. PubMed. 59(5). 479–87. 1 indexed citations
20.
Costa, Sílvia Figueiredo, Marisa H. Miceli, & Elias Anaissie. (2004). Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia?. The Lancet Infectious Diseases. 4(5). 278–286. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026